We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03014089
Recruitment Status : Completed
First Posted : January 9, 2017
Last Update Posted : December 9, 2019
Biomedical Advanced Research and Development Authority
Information provided by (Responsible Party):
ModernaTX, Inc.

Brief Summary:
The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.

Condition or disease Intervention/treatment Phase
Zika Virus Biological: mRNA-1325 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region
Study Start Date : December 21, 2016
Actual Primary Completion Date : July 2019
Actual Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Zika Virus

Arm Intervention/treatment
Experimental: mRNA-1325 Biological: mRNA-1325
Escalating dose levels

Placebo Comparator: Placebo
0.9% sodium chloride
Other: Placebo

Primary Outcome Measures :
  1. Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI) and adverse events considered related to study drug [ Time Frame: Through 13 months of study participation ]

Secondary Outcome Measures :
  1. Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample [ Time Frame: Through 13 months of study participation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • 18 to 49 years of age
  • Body mass index between 18 and 35 kg/m2
  • In good health as determined by medical history
  • Female subjects must be non pregnant and non lactating and meet one of the following criteria: a) post menopausal b) surgically sterile
  • Women of childbearing potential must agree to be heterosexually inactive or agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 3 months after the final vaccination
  • Male subjects must use an acceptable method of birth control throughout the entire study and agree to refrain from donation of sperm from the time of first vaccination until 3 months following the last vaccination
  • Agrees to comply with the study procedures and provides written informed consent
  • Has access to a consistent and reliable means of telephone contact and agrees to stay in contact with the study site for the duration of the study, to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study


  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
  • A history of active cancer (malignancy) in the last 10 years
  • Female of childbearing potential and has a positive pregnancy test at screening or on the day of vaccination
  • Administration of an investigational product within 60 days, or 5 half-lives, whichever is longer
  • Administration of any live attenuated vaccines within 4 weeks before enrollment or inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine during the active vaccination period
  • Prior administration of a vaccine for Zika or dengue vaccine, a history of confirmed Zika or dengue infection, or has lived in or visited any Zika-endemic area greater than 4 weeks in duration
  • Prior administration of investigational agent using formulations similar to mRNA-1325
  • A history of hypersensitivity or serious reactions to previous vaccinations
  • Any known or suspected autoimmune disease or immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination
  • A history of inflammatory arthritis
  • Any neurologic disorder
  • A history of febrile disease with arthritis or arthralgia within 2 weeks of dose administration.
  • Prior administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receive such products at any time during the study
  • Any chronic administration of an immunosuppressant or other immune modifying drug
  • Any acute illness at the time of enrollment
  • Any significant disorder of coagulation requiring ongoing or intermittent treatment
  • A history of idiopathic urticaria
  • A history of alcohol abuse or drug addiction
  • A positive test result for drugs of abuse
  • The subject has any abnormality or permanent body art (eg, tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site
  • Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results
  • A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
  • Donation of blood or blood products > 450 mL within 30 days of dosing.
  • Abnormal vital signs or screening safety laboratory test results including liver enzyme tests
  • Is an employee or first degree relative of the Sponsor, CRO, or study site personnel

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03014089

Layout table for location information
United States, California
San Diego, California, United States, 92108
United States, Florida
Melbourne, Florida, United States, 32934
United States, Illinois
Peoria, Illinois, United States, 61614
Sponsors and Collaborators
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority
Layout table for additonal information
Responsible Party: ModernaTX, Inc.
ClinicalTrials.gov Identifier: NCT03014089    
Other Study ID Numbers: mRNA-1325-P101
HHSO100201600029C ( Other Grant/Funding Number: Biomedical Advanced Research & Development Authority (BARDA) )
First Posted: January 9, 2017    Key Record Dates
Last Update Posted: December 9, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by ModernaTX, Inc.:
Zika vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Zika Virus Infection
Arbovirus Infections
Vector Borne Diseases
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections